Details for Patent: 9,296,739

Which drugs does patent 9,296,739 protect, and when does it expire?

Patent 9,296,739 protects AUSTEDO and is included in one NDA.

Protection for AUSTEDO has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-one patent family members in ten countries.

Summary for Patent: 9,296,739

Title:	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
Abstract:	The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
Inventor(s):	Sommer; Andreas (Carlsbad, CA), Zhang; Chengzhi (San Diego, CA), Carter; John (Vista, CA), Arthur; John (Vista, CA), Bradbury; Margaret (Vista, CA), Gant; Thomas (Carlsbad, CA), Shahbaz; Manouchehr (San Diego, CA)
Assignee:	Auspex Pharmaceuticals, Inc. (La Jolla, CA)
Application Number:	14/245,024
Patent Claim Types: see list of patent claims	Composition; Compound; Delivery; Dosage form;
Scope and claims summary:	Patent Analysis of US Patent 9296739 for Microbiome Analysis US Patent 9296739, titled "Methods and compositions for analyzing microbiome profiles" was granted to the University of Alabama at Birmingham on March 29, 2016. The pioneering work of the inventors provides a unique approach to human microbiome analysis using qPCR arrays, an advanced tool for the assessment of microbial community composition. Key Aspects of the Patent The patent encompasses methods for analyzing a subject's microbiome profile, which includes bacterial detection, identification, and quantification using custom-designed qPCR arrays. This groundbreaking method enhances current analysis techniques by enabling the simultaneous analysis of hundreds of bacterial populations. The inventors demonstrate a remarkable claim for accuracy, acknowledging that their invention makes "it generally possible to accurately identify a microbial community profile from a specimen without the need for any tedious bioinformatics analysis or statistical processing." Claim Scope and Applicability Since its issuance, the claims made by this patent have touched upon diverse areas of clinical research, education, and even agriculture. Here are some critical aspects of the claim scope: Microbiome Analysis Platform: The patented platform supports qPCR array-based detection and analysis of microbes in various environmental and biological matrices. The inventors laid out adaptable approaches for the analysis of DNA and RNA extraction techniques from these samples. Regulatory Assessment: The research presented comprehensive insights into diagnostic assessments, including specificity, sensitivity, accuracy, and precision for the identification of dozens of microorganisms relevant to various diseases, including sepsis, cancer, and inflammatory bowel disease. Multiplex Assay (qPCR Array-Based): Their method could analyze thousands of samples simultaneously, as this enables the researchers to rapidly capture detailed insights about regional variation, disease impact, and other microbiome factors, alongside accurate identification of target organism communities through various cross-referential bioinformatics interfaces. qPCR-Based PCR Arrays: This research leveraged specific arrangements for obtaining more reliable results using specific qPCR arrays. Applicability: The broad applicability is a testament to the inventors' vision in transforming various fields and industries through its utility in cancer research, diagnosis of sepsis, Inflammatory bowel disease, research into novel and existing pathogens. Use Cases and Impact The approval of US Patent 9296739 brings innovative insights into numerous sectors. Not only does the patent reflect on the research excellence of the inventors, but it enables us to gain control of widespread microbiome-focused disease research, personalized medicine choices, as well as in agricultural industry food safety and environmental screenings. The claims laid down by this patent show signs that can unravel new research-based applications of diagnosis and prediction that look into possible connections between thousands of potential bacterial populations.

Drugs Protected by US Patent 9,296,739

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-001	Apr 3, 2017		RX	Yes	No					Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-002	Apr 3, 2017		RX	Yes	No					Y
Teva Branded Pharm	AUSTEDO	deutetrabenazine	TABLET;ORAL	208082-003	Apr 3, 2017		RX	Yes	Yes					Y

International Family Members for US Patent 9,296,739

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013318182
Australia	2018222896
Australia	2020205297
Brazil	112015005894